- Conditions
- Asthma
- Interventions
- Budesonide 360ug, Budesonide 720ug, Budesonide 1440ug, Budesonide720ug 4 times, Placebo
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 913–936
of 4,628
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pain
- Interventions
- bupivacaine liposome injectable suspension, Placebo
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 14
- States / cities
- Mobile, Alabama • Englewood, Colorado • Miami, Florida + 9 more
- Conditions
- Cystic Fibrosis
- Interventions
- Placebo, QBW251
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 5 more
- Conditions
- Otherwise Healthy Overweight or Obese
- Interventions
- PHP-303, Placebo
- Drug · Other
- Lead sponsor
- pH Pharma
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Tumors
- Interventions
- NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod, NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo
- Drug
- Lead sponsor
- Nina Bhardwaj
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- Placebo, BIIB014 50mg, BIIB014 100mg
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Rheumatoid Arthritis
- Interventions
- GS-0272, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Glendale, California • Palo Alto, California • Upland, California + 11 more
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- PRX302, Placebo
- Drug · Other
- Lead sponsor
- Sophiris Bio Corp
- Industry
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 479 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 45
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Laguna Hills, California + 40 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- CFZ533, Placebo
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 5
- States / cities
- Anniston, Alabama • Miami, Florida • South Miami, Florida + 2 more
- Conditions
- Healthy
- Interventions
- AZD9742, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 23 Years to 45 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Healthy Volunteer
- Interventions
- A-005, Placebo
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Cardiovascular Disease
- Interventions
- FEIBA, Normal Saline
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Dendritic Cell -Mediated Rheumatic Diseases
- Interventions
- VIB1116, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Anniston, Alabama • Clearwater, Florida • Jacksonville, Florida + 5 more
- Conditions
- Healthy
- Interventions
- BIIB061, Placebo, 14C-BIIB061
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 20 Years to 55 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Evansville, Indiana • Madison, Wisconsin
- Conditions
- Fragile X Syndrome
- Interventions
- Baclofen, Memantine, Roflumilast, Placebo
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Healthy
- Interventions
- JNJ-70033093, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Nondependent Opioid Abuse, Episodic
- Interventions
- Placebo, MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Cystic Fibrosis
- Interventions
- MRT5005, Normal saline
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Denver, Colorado • Gainesville, Florida + 13 more
- Conditions
- Schwannomatosis, Schwannomas, Pain, Chronic
- Interventions
- Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo, Erenumab-Aooe Matching Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy
- Interventions
- GSK2336805 30 mg, GSK2336805 60 mg, GSK2336805 120 mg, TMC435 150 mg (Treatment A), GSK2336805 60 mg (Treatment B and part of Treatment C and D), TMC435 100 mg (part of Treatment C), TMC435 150 mg (part of treatment D)
- Drug
- Lead sponsor
- Janssen R&D Ireland
- Industry
- Eligibility
- 20 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Obesity
- Interventions
- Grape seed extract
- Dietary Supplement
- Lead sponsor
- California Baptist University
- Other
- Eligibility
- 18 Years to 29 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Riverside, California
- Conditions
- Healthy
- Interventions
- MTP-131 (Bendavia™)
- Drug
- Lead sponsor
- Mighty Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Glycogen Storage Disease Type III
- Interventions
- UX053, Placebo, Antipyretic, H2 Blocker, H1 Blocker
- Biological · Other · Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Orange, California • Atlanta, Georgia • Philadelphia, Pennsylvania + 1 more
- Conditions
- Obesity
- Interventions
- S-309309, Midazolam, Placebo
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas